Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil

Adv Enzyme Regul. 2001:41:151-7. doi: 10.1016/s0065-2571(00)00011-x.

Authors

M R Johnson¹, R B Diasio

Affiliation

¹ Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, UAB Comprehensive Cancer Center, University of Alabama at Birmingham, Box 600, Volker Hall 101, Birmingham, AL 35294, USA.

PMID: 11384742
DOI: 10.1016/s0065-2571(00)00011-x

No abstract available

MeSH terms

Antimetabolites, Antineoplastic / therapeutic use*
Antimetabolites, Antineoplastic / toxicity*
Dihydrouracil Dehydrogenase (NADP)
Female
Fluorouracil / therapeutic use*
Fluorouracil / toxicity*
Humans
Leukocytes, Mononuclear / metabolism
Male
Oxidoreductases / deficiency*
Phenotype

Substances

Antimetabolites, Antineoplastic
Oxidoreductases
Dihydrouracil Dehydrogenase (NADP)
Fluorouracil